Free Trial
NASDAQ:VANI

Vivani Medical Q2 2024 Earnings Report

Vivani Medical logo
$1.27 -0.01 (-0.78%)
As of 10:25 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vivani Medical EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.12
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Vivani Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vivani Medical Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Conference Call Date
Wednesday, August 14, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Vivani Medical's Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Vivani Medical Earnings Headlines

Short Interest in Vivani Medical, Inc. (NASDAQ:VANI) Declines By 32.5%
September 2025's Promising Penny Stock Opportunities
Out of 18,347 Cryptocurrencies... This is the ONLY One
The Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should buy in this market, this token might just be it.tc pixel
See More Vivani Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vivani Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vivani Medical and other key companies, straight to your email.

About Vivani Medical

Vivani Medical (NASDAQ:VANI) Solutions, Inc. (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity. These products aim to reduce complications associated with percutaneous biopsies while facilitating efficient sample collection and handling, helping clinicians deliver faster and more accurate diagnoses.

Vivani Medical serves a broad customer base that encompasses hospitals, outpatient imaging centers and pathology service providers across the United States. In addition to its direct‐sales model, the company has established distribution partnerships to extend its reach into select European and Latin American markets, supporting growing international adoption of its technologies.

Founded in 2016 and headquartered in the United States, Vivani Medical became a publicly traded company in mid-2021, listing its common stock on the Nasdaq Capital Market under the ticker symbol “VANI.” The company’s leadership team brings together experienced professionals in medical device innovation, regulatory affairs and commercial operations, driving ongoing efforts to expand its product pipeline and reinforce its position in the interventional radiology market.

View Vivani Medical Profile

More Earnings Resources from MarketBeat